Study of Novel Types of Familial Diabetes Insipidus

The recruitment status of this study is unknown because the information has not been verified recently.

Verified February 2006 by Office of Rare Diseases (ORD). Recruitment status was Active, not recruiting

First Received on October 18, 1999. Last Updated on February 21, 2006 History of Changes

Sponsor:	National Center for Research Resources (NCRR)
Collaborator:	Northwestern University
Information provided by:	Office of Rare Diseases (ORD)
ClinicalTrials.gov Identifier:	NCT00004364

Purpose

OBJECTIVES:

I. Define the phenotype and genotype of previously unrecognized types of familial diabetes insipidus (FDI) in kindreds with atypical or novel forms of FDI.

Condition	Intervention
Diabetes Insipidus	Drug: desmopressin

Study Type:	Observational
Study Design:	Primary Purpose: Screening

Resource links provided by NLM:

Genetics Home Reference related topics: 6q24-related transient neonatal diabetes mellitus neurohypophyseal diabetes insipidus

MedlinePlus related topics: Diabetes Insipidus Endocrine Diseases

Drug Information available for: Desmopressin Desmopressin acetate

U.S. FDA Resources

Further study details as provided by Office of Rare Diseases (ORD):

Estimated Enrollment:	5
Study Start Date:	December 1995

Detailed Description:

PROTOCOL OUTLINE: Participants undergo a series of tests to determine the presence, absence, cause, natural history, clinical status, and mode of inheritance of their type of diabetes insipidus (DI). The studies include measurements of basal fluid intake and urine output, plasma vasopressin during standard fluid deprivation or waterload/saline infusion tests, and changes in water balance during a therapeutic trial of DDAVP. If clinically indicated, echocardiograms and assays of plasma catecholes and renin are also completed.

Linkage analysis is performed for all participants; kindreds with the Marfan-like syndrome are also studied for the fibrillin-1 genotype.

Participants determined to have DI are treated with desmopressin for 2 days.

Eligibility

Ages Eligible for Study:	6 Months to 70 Years
Genders Eligible for Study:	Both
Accepts Healthy Volunteers:	No

Criteria

Familial diabetes insipidus (DI) in atypical or novel form, e.g.: Dipsogenic DI Neurohypophyseal DI
Affected and unaffected members of kindreds eligible

Contacts and Locations

Please refer to this study by its ClinicalTrials.gov identifier: NCT00004364

Sponsors and Collaborators

National Center for Research Resources (NCRR)

Northwestern University

Investigators

Study Chair:

Gary L. Robertson

Northwestern University

More Information

No publications provided

ClinicalTrials.gov Identifier:	NCT00004364 History of Changes
Other Study ID Numbers:	199/11939, NU-570
Study First Received:	October 18, 1999
Last Updated:	February 21, 2006
Health Authority:	United States: Federal Government

Keywords provided by Office of Rare Diseases (ORD):

diabetes insipidus
endocrine disorders
rare disease

Additional relevant MeSH terms:

Diabetes Mellitus
Diabetes Insipidus
Diabetes Insipidus, Neurogenic
Glucose Metabolism Disorders
Metabolic Diseases
Endocrine System Diseases
Kidney Diseases
Urologic Diseases
Pituitary Diseases
Deamino Arginine Vasopressin
Arginine Vasopressin

Antidiuretic Agents
Natriuretic Agents
Physiological Effects of Drugs
Pharmacologic Actions
Hemostatics
Coagulants
Hematologic Agents
Therapeutic Uses
Cardiovascular Agents
Vasoconstrictor Agents

ClinicalTrials.gov processed this record on February 12, 2012